2020-08-07T11:50:20-05:00 2019-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2019-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW No 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2020-08-07 1 Jie Chen CPA P01049760 7038930300 2020-08-07 173.73.98.186 2020-08-07 12:48:15 ED P 4E34592AB1F6423AB9D06C25827E64500E8BEDD1 63C1C0B9F93C8B40CBCDC4B3DDBC3363D21A7384 2019 2020-09-23 17:36:50Z Amy Finan 2175 K Street NW No 400 Washington DC 20037 9626607 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 10 9 40 6 0 0 10410527 9462400 0 0 50519 68713 0 17077 10461046 9548190 1858021 2584662 0 0 3723726 4288897 0 0 278408 4830598 6886926 10412345 13760485 48701 -4212295 16463026 12943151 3362329 4012291 13100697 8930860 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 4554216 2170035 Vaccine Access and Uptake:Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by routine immunization. Sabin works with key decision makers and immunization experts at the country and global level to build resilient, sustainable national immunization programs to reach every child.Sabin is an adviser, a convener and a catalyst of systemic change, bringing together researchers, national government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. In order to make informed decisions about vaccine introduction and implementation, countries require high-quality information and evidence. Sabin supports surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. By establishing and sharing best practices, we help countries evaluate and streamline vaccine introduction and scale-up.Collaboration across continents and sectors is critical to extend the benefits of immunization around the globe. Through our international scientific meetings, Sabin fosters dialogue between global health leaders, researchers and implementers to unify global efforts to accelerate access to new and under-utilized vaccines. 5130298 64627 Vaccine Knowledge and Innovation:The immunization landscape is constantly evolving. Immunization professionals are faced with the challenge of staying up-to-date on new vaccines, changing policies and recommendations, and developments in vaccine science, while the general public is inundated with information, making it difficult to discern truth from fiction.Sabin drives meaningful, well-informed conversations on emerging and established issues across the field of immunization and provides training and education on the latest in vaccine science and policy to immunization professionals, policymakers and journalists, among others.Sabin fosters a global community that enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts.Sabin works to shape the vaccine conversation by amplifying reliable information on vaccines. We work to dispel misinformation, understand the social drivers of vaccination decisions through research, and understand the role of social media on vaccine confidence. We serve as a leading voice on critical issues in global immunization, including vaccine confidence, vaccine safety and global health innovation. We also work to drive more effective, accurate media coverage on vaccines by equipping journalists and health professionals with the latest information on disease burden and immunization. Sabin drives vaccine innovation by bringing together big thinkers from various industries to accelerate the development of a universal influenza vaccine. 1878388 350000 Vaccine Research and Development:The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's R&D strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.Ebola has taken the lives of more than 13,000 people in recent years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is developing vaccines based on technology for three clinical-stage candidate vaccines licensed from GSK. The agreement involves prophylactic candidate vaccines to protect against Ebola Zaire, Ebola Sudan and Marburg virus, all based on GSK's proprietary ChAd3 platform. In an additional agreement, Sabin is partnering with the Vaccine Research Center at the National Institute of Allergy and Infectious Disease to continue development of these vaccines. 11562902 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 39 0 1 40 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2175 K Street NW No 400 Washington DC 20037 Finan Amy Trustee, Officer - CEO; Ex Officio 40.00 X X 372297 0 22010 Dubovsky Filip Trustee (as of 8/17/19) 2.00 X 0 0 0 Fox Elizabeth Trustee (as of 7/1/19) 2.00 X 0 0 0 Holman Wendy Trustee 2.00 X 0 0 0 Hoos Axel Trustee, Chairman 2.00 X X 0 0 0 Omer Saad Trustee (as of 7/1/19) 2.00 X 0 0 0 Rabinovich Regina Trustee 2.00 X 0 0 0 Salisbury David Trustee (as of 12/1/19) 2.00 X 0 0 0 Shea Jaqueline Trustee (as of 7/1/19) 2.00 X 0 0 0 Thoren Peter Trustee, Vice Chairman 2.00 X X 0 0 0 Marine Michael Trustee, Secretary (until 12/10/19) 2.00 X X 0 0 0 Russell Philip Trustee (until 12/10/19) 2.00 X 0 0 0 Davis Brian Officer - COO 40.00 X 290903 0 35551 Gellin Bruce Officer - President, Global Immunization 40.00 X 359118 0 17139 Fluder Jennifer Director, Global Community Engagement 40.00 X 146178 0 7031 Garrett Denise Vice President, Typhoid Programs 40.00 X 226253 0 25632 Hayward Tara Vice President, Resource Development 40.00 X 175153 0 23257 Knobler Stacey Director, Influenza Vaccine Innovations 40.00 X 174471 0 7803 Woodin Mary Beth Vice President, Communications 40.00 X 190580 0 29235 1934953 0 167658 12 0 1 0 Dalberg Consulting US LLC 99 Madison Ave Floor 17 New York NY 10016 Platform development for Boost program 542442 BDO USA LLP PO Box 642743 Pittsburgh PA 152642743 Support R&D QA,PM,& govt. compliance 495265 The Boston Consulting Group Inc PO Box 75200 Chicago IL 606755200 Review business plan for Flu program 399072 Cult Health 261 Fifth Avenue Suite 1002 New York NY 10016 Branding & promotions Flu prog. 343117 The Aspen Institute 2300 N Street NW Washington DC 20037 Convene stakeholders for VAD program 299247 9 1487221 7975179 9462400 68713 68713 78417 78417 0 0 Gain on foreign curren 900099 10477 10477 Tax refund 900099 6600 6600 17077 9548190 0 0 85790 X 482048 482048 2102614 2102614 1097020 779567 250224 67229 2593787 1857600 576673 159514 138019 52755 79604 5660 233227 182859 34372 15996 226844 160088 52380 14376 88133 88133 21601 21601 3338513 3233107 105001 405 763461 760648 2813 108295 55778 51192 1325 63528 30594 30301 2633 499673 499673 450743 440166 6579 3998 1058176 1041062 17114 369352 252600 116752 43511 43511 Dues/subscriptions 36522 21682 7836 7004 Recruitment 24170 16618 7552 Miscellaneous 20712 4455 15989 268 Books & publications 536 528 8 13760485 11562902 1919175 278408 1832931 2222415 10611306 5581069 393095 1739049 8150 269 116160 197831 1521946 617884 1020814 904062 268217 338703 2212353 1959753 16463026 12943151 1424511 2087136 5969 6908 1931849 1918247 3362329 4012291 X 1774230 1204781 11326467 7726079 13100697 8930860 16463026 12943151 X -4212295 52245 -9787 X X 0 1 X 1 0 X 17896741 14719648 8075830 10410527 9462400 60565146 17896741 14719648 8075830 10410527 9462400 60565146 31175192 29389954 23756 27774 27008 98272 147130 323940 31650 15222 17077 63949 60953035 39300 0.48220 0.51300 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 13760485 13760485 838024 209506 0 0 1000000 678334 669505 838024 3185863 4778795 4263 980 59 5302 250000 169584 167376 209506 796466 1194699 784 784 1192938 292302 900636 329008 325582 3426 904062 Deferred rent 1520546 Deferred compensation liability 391732 Security deposit 5969 1918247 X 9783358 52245 104506 156751 9626607 -78417 -78417 9548190 13943408 104506 78417 182923 13760485 0 13760485 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. Part XI, Line 4b - Other Adjustments: Rental Expense -78,417. Part XII, Line 2d - Other Adjustments: Rental Expense 78,417. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites, Vaccine Acceptance Small Grants Program awardee 1634958 South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, 0 0 Grants to recipients located in region Dengue vaccine effectiveness study & clinical trial site 74515 Sub-Saharan Africa 0 0 Grants to recipients located in region Vaccine acceptance small grants program awardee 21596 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium 0 0 Grants to recipients located in region Bulk drug substance production for ebola/marburg, Vaccine Acceptance Small Grants Program awardee 371546 0 0 0 0 0 0 2102615 0 2102615 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 847954 EFT South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, Dengue vaccine effectiveness study 74515 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 550518 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 215000 EFT Sub-Saharan Africa Vaccine acceptance small grants program awardee 21596 EFT Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Bulk drug substance production for ebola/marburg 350000 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine acceptance small grants program awardee 21486 EFT 7 0 Vaccine acceptance small grants program awardee Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgiu 1 21546 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). Part III Accounting Method: 1 Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501C3 120000 Typhoid study site National Foundation for the Centers for Disease Control and Prevention 600 Peachtree Street NE Suite 1000 Atlanta GA 30308 582106707 501C3 115000 Typhoid study site Stanford University Lockbox PO Box 44253 San Francisco CA 94144 941156365 501C3 247048 Typhoid study site 3 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy Trustee, Officer - CEO; Ex Officio 342297 0 30000 0 0 0 9389 0 12621 0 394307 0 0 0 Davis Brian Officer - COO 260903 0 30000 0 0 0 9982 0 25569 0 326454 0 0 0 Gellin Bruce Officer - President, Global Immuniza 299118 0 60000 0 0 0 8768 0 8371 0 376257 0 0 0 Fluder Jennifer Director, Global Community Engagemen 146178 0 0 0 0 0 992 0 6039 0 153209 0 0 0 Garrett Denise Vice President, Typhoid Programs 216253 0 10000 0 0 0 8722 0 16910 0 251885 0 0 0 Hayward Tara Vice President, Resource Development 165153 0 10000 0 0 0 6747 0 16510 0 198410 0 0 0 Knobler Stacey Director, Influenza Vaccine Innovati 174471 0 0 0 0 0 6094 0 1709 0 182274 0 0 0 Woodin Mary Beth Vice President, Communications 180580 0 10000 0 0 0 7455 0 21780 0 219815 0 0 0 Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Transcription/translation service: Program service expenses 17,194. Management and general expenses 0. Fundraising expenses 0. Total expenses 17,194. Consultants: Program service expenses 2,906,666. Management and general expenses 105,001. Fundraising expenses 405. Total expenses 3,012,072. Contractor: Program service expenses 309,247. Management and general expenses 0. Fundraising expenses 0. Total expenses 309,247. Form 990, Part XI, line 9: Return of contribution income -9,787. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.